The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Verywell Health on MSN2d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for ... of people around the world live with major depressive disorder (MDD), making it the most commonly ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...
TheHealthSite.com on MSN6d
US FDA Approves First Of Its Kind Ketamine-Based Nasal Spray To Treat Depression: Know All About This DrugThe US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback